References
1. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, et al. Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy? Circulation. 2006 Feb 14;113(6):776–82.
2. Xie J, Weil MH, Sun S, Tang W, Sato Y, Jin X, et al. High-Energy Defibrillation Increases the Severity of Postresuscitation Myocardial Dysfunction. Circulation. 1997 Jul 15;96(2):683–8.
3. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure. N Engl J Med. 2008 Sep 4;359(10):1009–17.
4. Tereshchenko LG, Faddis MN, Fetics BJ, Zelik KE, Efimov IR, Berger RD. Transient Local Injury Current in Right Ventricular Electrogram after ICD Shock Predicts Heart Failure Progression. J Am Coll Cardiol. 2009 Aug 25;54(9):822–8.
5. Azoulay LD, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2020;37(1):17–23.
6. Taha A, Assaf O, Champsi A, Nadarajah R, Patel PA. Outcomes after transvenous defibrillator implantation in cardiac sarcoidosis: A systematic review. J Arrhythmia. 2022;38(5):710–22.
7. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Pa℡ AR, et al. Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis. J Cardiovasc Electrophysiol. 2012;23(9):925–9.
8. Halawa A, Jain R, Turagam MK, Kusumoto FM, Woldu HG, Gautam S. Outcome of implantable cardioverter defibrillator in cardiac sarcoidosis: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2020 Aug;58(2):233–42.
9. Franke KB, Marshall H, Kennewell P, Pham HD, Tully PJ, Rattanakosit T, et al. Risk and predictors of sudden death in cardiac sarcoidosis: A systematic review and meta-analysis. Int J Cardiol. 2021 Apr 1;328:130–40.
10. Mathijssen H, Bakker ALM, Balt JC, Akdim F, van Es HW, Veltkamp M, et al. Predictors of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2022;33(6):1272–80.
11. Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, et al. Cardiac Sarcoidosis: Electrophysiological Outcomes on Long-Term Follow-Up and the Role of the Implantable Cardioverter-Defibrillator. J Cardiovasc Electrophysiol. 2014;25(2):171–6.
12. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005 Jul 15;96(2):276–82.
13. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012 Jun;9(6):884–91.
14. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. EP Eur. 2013 Mar 1;15(3):347–54.
15. Bandyopadhyay D, Sahoo D, Zein J, Brunken RC, Tchou PJ, Culver DA. Outcome of cardiac sarcoidosis after radiofrequency ablation and placement of AICD- A propensity matched analysis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2015 Jun 22;32(1):70–9.
16. Takaya Y, Kusano K, Nishii N, Nakamura K, Ito H. Early and frequent defibrillator discharge in patients with cardiac sarcoidosis compared with patients with idiopathic dilated cardiomyopathy. Int J Cardiol. 2017 Aug 1;240:302–6.
17. Kouranos V, Khattar RS, Okafor J, Ahmed R, Azzu A, Baksi JA, et al. Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation. Eur J Heart Fail [Internet]. [cited 2024 Jan 13];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.3057
18. Patel N, Kalra R, Doshi R, Arora H, Bajaj NS, Arora G, et al. Hospitalization Rates, Prevalence of Cardiovascular Manifestations, and Outcomes Associated With Sarcoidosis in the United States. J Am Heart Assoc. 2018 Jan 23;7(2):e007844.
19. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial Difference in Sarcoidosis Mortality in the United States. Chest. 2015 Feb;147(2):438.
20. Hassan A, Ramphul K, Ahmed R, Hasan A, Farhan M, Ahmad H, et al. Abstract 14474: Racial Disparities in Arrhythmias Among Patients With Cardiac Sarcoidosis in the United States From 2016-2020. Circulation. 2023 Nov 7;148(Suppl_1):A14474–A14474.
21. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm. 2014 Jul;11(7):1304–23.
22. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm. 2018 Oct;15(10):e73–189.
23. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997–4126.
24. Nordenswan HK, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M, et al. Outcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular Block. Circ Arrhythm Electrophysiol. 2018 Aug;11(8):e006145.
25. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1109–15.
26. Velangi PS, Chen KHA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al. Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. JACC Cardiovasc Imaging. 2020 Jun;13(6):1395–405.
27. Smedema JP, van Geuns RJ, Ainslie G, Ector J, Heidbuchel H, Crijns HJGM. Right ventricular involvement in cardiac sarcoidosis demonstrated with cardiac magnetic resonance. ESC Heart Fail. 2017;4(4):535–44.
28. Ekström K, Lehtonen J, Nordenswan HK, Mäyränpää MI, Räisänen-Sokolowski A, Kandolin R, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019 Oct 1;40(37):3121–8.
29. Kirkfeldt RE, Johansen JB, Nohr EA, Jørgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014 May;35(18):1186–94.
30. Lin G, Brady PA, Meverden RA, Hodge DO, Uslan DZ, Hayes DL. Age and Gender Trends in Implantable Cardioverter Defibrillator Utilization. J Interv Card Electrophysiol Int J Arrhythm Pacing. 2008 Jun;22(1):65–70.
31. Girerd N, Nonin E, Pinot J, Morel E, Flys C, Scridon A, et al. Risk of Sprint Fidelis defibrillator lead failure is highly dependent on age. Arch Cardiovasc Dis. 2011;104(6–7):388–95.
32. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225–37.
33. Tateishi R, Suzuki M, Shimizu M, Shimada H, Tsunoda T, Miyazaki H, et al. Risk prediction of inappropriate implantable cardioverter-defibrillator therapy using machine learning. Sci Rep. 2023 Nov 9;13(1):19586.